We are excited to share that we completed our transaction with Novo Holdings! As a private company with Novo Holdings’ partnership and support, we are well-positioned to deliver unparalleled outcomes for our customers and the patients we serve. Across our remaining network of more than 40 global sites, we will continue to provide our customers with the latest technology and capabilities and partner with them to expand patient access to much-needed treatments and cures. The entire Catalent team remains focused on our mission to develop, manufacture and supply products that help people live better, healthier lives. Learn more about our announcement here:
Half-day program featuring key opinion leaders aims to explore significant innovation & improvements in viral-vector based gene therapies.
